文献速递肿瘤 PET/CT

PSMA PET/CT 提高原发性肺癌分期准确性并成像新生血管化相关特征

PSMA PET/CT for Improved Staging Accuracy and Imaging of Neovascularization-associated Features in Primary Lung Cancer.
PubMed 文献 · Clin Nucl Med · 2025-07-29

这项回顾性研究纳入39例患者(27例原发性肺癌、12例良性病变),评估PSMA PET/CT鉴别原发性肺癌与良性病变及淋巴结分期的效能。PSMA PET/CT鉴别原发性肺癌的SUVmax AUC为0.89(cutoff 2.3 g/mL),纵隔淋巴结识别AUC为0.86(cutoff 2.5 g/mL);与FDG PET/CT相比假阳性淋巴结检出率更低,使60%(12/20)病例N分期重新分类。PSMA摄取与PSMA H-score(R=0.63)、CD31微血管密度(R=0.77)、VEGFA H-score(R=0.65)显著相关。

要点

  • PSMA PET/CT鉴别原发性肺癌与良性病变SUVmax AUC为0.89(cutoff 2.3 g/mL)。
  • 纵隔淋巴结识别AUC为0.86(cutoff 2.5 g/mL),较FDG PET/CT假阳性率更低。
  • PSMA PET/CT使60%(12/20)病例N分期重新分类。

核心结论

  • PSMA PET在原发性肺癌中的摄取高于良性病变,改善淋巴结分期,并显示其作为新生血管化生物标志物和优化治疗的潜力。

研究设计与样本

  • 回顾性研究纳入39例患者(27例原发性肺癌、12例良性病变),于2021年4月至2024年7月期间接受PSMA PET/CT(伴或不伴FDG PET/CT),其中11例手术病例进行PSMA、VEGFA和CD31免疫组化评估。

主要发现

  • PSMA PET/CT鉴别原发性肺癌与良性病变的SUVmax AUC为0.89(cutoff 2.3 g/mL),纵隔淋巴结识别AUC为0.86(cutoff 2.5 g/mL)。
  • 与FDG PET/CT相比,PSMA PET/CT假阳性淋巴结检出率更低,导致60%(12/20)病例N分期重新分类。
  • 肺内病灶PSMA PET摄取与PSMA H-score显著相关(R=0.63,p<0.05),与CD31评估的微血管密度显著相关(R=0.77,p<0.01),与VEGFA H-score显著相关(R=0.65,p<0.05)。
  • FDG摄取与上述指标无相关性。

关键数值与推荐

  • PSMA PET/CT鉴别原发性肺癌与良性病变的SUVmax cutoff为2.3 g/mL,AUC为0.89。
  • 纵隔淋巴结识别的SUVmax cutoff为2.5 g/mL,AUC为0.86。
  • PSMA PET摄取与PSMA H-score相关性R=0.63(p<0.05),与CD31微血管密度相关性R=0.77(p<0.01),与VEGFA H-score相关性R=0.65(p<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific membrane antigen (PSMA), expressed in neovascular endothelial cells of various malignancies including lung cancer (LC), highlights its potential as a biomarker for neovascularization. This study aimed to investigate the diagnostic efficacy of PSMA PET/CT in primary lung cancer (PLC), as well as to explore its role in staging and neovascularization detection in PLC. PATIENTS AND METHODS: This retrospective study included 39 patients (27 with PLC, 12 with benign lesions) who underwent PSMA PET/CT, with or without FDG PET/CT, between April 2021 and July 2024. Lesion characteristics and immunohistochemistry for PSMA, VEGFA, and CD31 were assessed in 11 surgical cases. Statistical analyses included the Mann-Whitney U test and Spearman correlation ( p <0.05). RESULTS: Our study demonstrated that PSMA PET/CT effectively differentiates PLC from benign lesions, achieving a high SUVmax AUC of 0.89 (cutoff: 2.3 g/mL) and a mediastinal lymph node (LN) identification AUC of 0.86 (cutoff: 2.5 g/mL). Compared with FDG PET/CT, PSMA PET/CT exhibited a lower false-positive LN detection rate, resulting in N-stage reclassification in 60% (12/20) of cases. PSMA PET uptake in intrapulmonary lesions correlated significantly with the PSMA H-score (R=0.63, p <0.05), CD31-assessed microvessel density (R=0.77, p <0.01), and VEGFA H-score (R=0.65, p <0.05), while FDG uptake showed no correlation. CONCLUSIONS: PSMA PET shows higher uptake in PLC than in benign lesions, improves LN staging, and reveals its potential as a biomarker for neovascularization and treatment optimization in LC.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhao R, Liu J, Liang W, et al. PSMA PET/CT for Improved Staging Accuracy and Imaging of Neovascularization-associated Features in Primary Lung Cancer. Clin Nucl Med. 2025. PMID: 40829160. doi:10.1097/RLU.0000000000006061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。